ClinicalTrials.gg
TerminatedNCT05071183Updated Apr 2, 2024Results posted

A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors

A Phase 1/2 interventional study of TPX-0005 and Trametinib in KRAS Mutation-Related Tumors, Metastatic Solid Tumor and Advanced Solid Tumor, sponsored by Turning Point Therapeutics, Inc.. Terminated at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-02.

Sponsored by Turning Point Therapeutics, Inc. (part of Bristol-Myers Squibb) · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Inability to achieve and optimize a dose that could provide a positive benefit risk profile

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies in Neoplasm Metastasis by Bristol-Myers Squibb — 1 open to participants now, 8 under way, 1 of them phase 3. Neoplasm Metastasis · Bristol-Myers Squibb.

Enrollment
40th of 44
9 · median 66
Started
2021
with 3 others
Phase 1/2
9 of 50
1 open now
Registered
41st of 50
by date

Among the 50 studies in Neoplasm Metastasis by Bristol-Myers Squibb, this one is the 40th largest by enrollment of the 44 interventional ones that give a count, is one of 4 that started in 2021, is one of 9 in phase 1/2, and was the 41st registered.

Neoplasm Metastasis

4,046 studies on the registry are indexed under Neoplasm Metastasis; 889 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

1 of the 50 studies in Neoplasm Metastasis by Bristol-Myers Squibb is open now, in 11 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 690 Neoplasm Metastasis studies recruiting now, 537 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Neoplasm Metastasis by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

A Phase 1b/2 Study of Repotrectinib in Combination with Other Anticancer Therapies for the Treatment of Subjects with KRAS-Mutant Advanced Solid Tumors (TRIDENT-2)

Read the detailed description

Phase 1 Dose Escalation: To evaluate tolerability of repotrectinib at increasing dose levels in combination with other anticancer therapies for the treatment of subjects with locally advanced or metastatic KRAS-mutant solid tumors

Phase 2 Efficacy Evaluation: Investigate the anti-tumor efficacy and safety of repotrectinib in combination with other anticancer therapies for the treatment of patients with locally advanced or metastatic KRAS-mutant solid tumors.

03

Conditions studied

  • KRAS Mutation-Related Tumors
  • Metastatic Solid Tumor
  • Advanced Solid Tumor

Browse trials for

Keywords

  • KRAS
  • KRAS-mutant
  • Metastatic Solid Tumor
  • Advanced Solid Tumor
  • Advanced/metastatic disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 (or as required by local regulation).
  • Histological or cytological confirmation of unresectable or solid tumor harboring a KRAS mutation.
  • No more than 3 prior standard treatments appropriate for tumor type and stage of disease.
  • performance status ≤ 1.
  • Existence of (according to [RECIST v1.1] criteria).
  • Subjects with asymptomatic and/or asymptomatic are eligible.
  • Adequate organ function.

Exclusion criteria

Exclusion Criteria:

  • Major surgery within four weeks of the start of treatment.
  • Previous other cancer requiring treatment within the previous two years.
  • cardiovascular disease.
  • Any of the following cardiac criteria:
  • Mean resting interval (QTc) > 470 msec obtained from three ECGs and any factors that increase the risk of QTc prolongation or arrhythmic events
  • Any clinically important abnormalities in rhythm, conduction, or morphology of resting
  • Known clinically significant active infections not controlled with systemic treatment (bacterial, fungal, viral including positivity).
  • Gastrointestinal disease or other malabsorption syndromes that would impact drug absorption.
  • Subjects being treated with or anticipating the need for treatment with strong inhibitors or inducers.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    TPX-0005 + Trametinib

    TPX-0005 + Trametinib Dose Escalation and Dose Expansion Dose escalation: KRAS G12D mutant advanced solid tumors. Dose expansion: KRAS G12D locally advanced or metastatic NSCLC

    Drug: TPX-0005 · Drug: Trametinib

Interventions

  • Oral TPX-0005 capsules

    Also known as: repotrectinib

  • Oral trametinib tablets

    Also known as: Mekinist

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose Limiting Toxicities

    Number of participants with first cycle DLTs to determine Mean Tolderable Dose (MTD) and/or RP2D. A DLT is defined as an adverse event (AE) or abnormal laboratory value assessed as unrelated to disease progression, intercurrent illness, or concomitant medications that meets the criteria defined in each subprotocol. The MTD is defined as the highest dose level of repotrectinib given in combination with other anticancer therapy observed to cause a DLT in fewer than 33% of the treated subjects in the first treatment cycle (i.e., Cycle 1).

    Time frame: From initial dose to end of first cycle of treatment, approximately 28 days

Secondary outcomes

  1. Overall Response Rate (ORR) Assessed the Investigator Using RECIST v1.1.

    The ORR will be defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR). A confirmed response is a response that persists on a repeat imaging performed at least 4 weeks after initial documentation of response. Participants with a confirmed objective response (CR or PR) will be referred to as responders. Radiographic confirmation of objective tumor response (CR or PR) or disease progression will be based on RECIST v1.1. The ORR will be reported as the percentage of responders by RECIST v1.1 along with the corresponding two-sided 95% Clopper-Pearson exact CI. Complete Response (CR) = Disappearance of all target lesions Partial Response (PR) = \>=30% decrease in the sum diameters of target lesions.

    Time frame: From screening to end of treatment approximately 10 months

  2. Cmax of Repotrectinib

    Cmax is defined as maximum plasma concentration of the drug.

    Time frame: At Cycle 1 Day 1 and Cycle 1 Day 22

  3. Tmax of Repotrecitinib

    Tmax is defined is the time to maximum plasma concentration

    Time frame: At Cycle 1 Day 1 and Cycle 1 Day 22

  4. AUC 0-24 of Repotrecitinib

    Area under the plasma concentration time-curve. AUC from time 0 to 24 hours after dose.

    Time frame: At Cycle 1 Day 1 and Cycle 1 Day 22

  5. Cmax of Trametinib

    Cmax is defined as maximum plasma concentration of the drug.

    Time frame: At Cycle 1 Day 1 and Cycle 1 Day 22

  6. Tmax of Trametinib

    Tmax is defined is the time to maximum plasma concentration

    Time frame: At Cycle 1 Day 1 and Cycle 1 Day 22

  7. AUC 0-24 of Trametinib

    Area under the plasma concentration time-curve. AUC from time 0 to 24 hours after dose.

    Time frame: At Cycle 1 Day 1 and Cycle 1 Day 22

07

Results

Posted Apr 2, 2024
Limitations and caveats
Study terminated early by sponsor before initiation of phase 2, so phase 2 outcome measures and endpoint data will not be reported.

Participant flow

Participant flow — Overall Study
MilestoneDose Level 1Dose Level 2Dose Level -2a
Started252
Completed000
Not completed252
Withdrew: Death120
Withdrew: Other reasons132

Outcome measures

PrimaryNumber of Participants With Dose Limiting Toxicities

Number of participants with first cycle DLTs to determine Mean Tolderable Dose (MTD) and/or RP2D. A DLT is defined as an adverse event (AE) or abnormal laboratory value assessed as unrelated to disease progression, intercurrent illness, or concomitant medications that meets the criteria defined in each subprotocol. The MTD is defined as the highest dose level of repotrectinib given in combination with other anticancer therapy observed to cause a DLT in fewer than 33% of the treated subjects in the first treatment cycle (i.e., Cycle 1).

Time frame:
From initial dose to end of first cycle of treatment, approximately 28 days
Reported as:
Count of participants · Participants
Number of Participants With Dose Limiting Toxicities
ParticipantsDose Level 1Dose Level 2Dose Level -2a
Number of Participants With Dose Limiting Toxicities202
SecondaryOverall Response Rate (ORR) Assessed the Investigator Using RECIST v1.1.

The ORR will be defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR). A confirmed response is a response that persists on a repeat imaging performed at least 4 weeks after initial documentation of response. Participants with a confirmed objective response (CR or PR) will be referred to as responders. Radiographic confirmation of objective tumor response (CR or PR) or disease progression will be based on RECIST v1.1. The ORR will be reported as the percentage of responders by RECIST v1.1 along with the corresponding two-sided 95% Clopper-Pearson exact CI. Complete Response (CR) = Disappearance of all target lesions Partial Response (PR) = \>=30% decrease in the sum diameters of target lesions.

Time frame:
From screening to end of treatment approximately 10 months
Reported as:
Number · Percentage of Participants
Overall Response Rate (ORR) Assessed the Investigator Using RECIST v1.1.
Percentage of ParticipantsDose Level 1Dose Level 2Dose Level -2a
Overall Response Rate (ORR) Assessed the Investigator Using RECIST v1.1.—0 (0.0 to 60.2)—
SecondaryCmax of Repotrectinib

Cmax is defined as maximum plasma concentration of the drug.

Time frame:
At Cycle 1 Day 1 and Cycle 1 Day 22
Reported as:
Geometric mean · ng/mL
Cmax of Repotrectinib
ng/mLDose Level 1Dose Level 2Dose Level -2a
Cycle 1 Day 1656.85 ± 37.88570.86 ± 66.02569.27 ± 20.26
Cycle 1 Day 22—411.83 ± 49.37—
SecondaryTmax of Repotrecitinib

Tmax is defined is the time to maximum plasma concentration

Time frame:
At Cycle 1 Day 1 and Cycle 1 Day 22
Reported as:
Median · hours (h)
Tmax of Repotrecitinib
hours (h)Dose Level 1Dose Level 2Dose Level -2a
Cycle 1 Day 13.00 (2.00 to 4.00)2.00 (1.00 to 6.00)4.00 (4.00 to 4.00)
Cycle 1 Day 22—3.00 (2.00 to 4.00)—
SecondaryAUC 0-24 of Repotrecitinib

Area under the plasma concentration time-curve. AUC from time 0 to 24 hours after dose.

Time frame:
At Cycle 1 Day 1 and Cycle 1 Day 22
Reported as:
Geometric mean · h*ng/mL
AUC 0-24 of Repotrecitinib
h*ng/mLDose Level 1Dose Level 2Dose Level -2a
Cycle 1 Day 16208.74 ± 82.596692.13 ± 57.488327.26 ± 25.27
Cycle 1 Day 22—5223.89 ± 31.06—
SecondaryCmax of Trametinib

Cmax is defined as maximum plasma concentration of the drug.

Time frame:
At Cycle 1 Day 1 and Cycle 1 Day 22
Reported as:
Geometric mean · ng/mL
Cmax of Trametinib
ng/mLDose Level 1Dose Level 2Dose Level -2a
Cycle 1 Day 115.24 ± 20.553.30 ± 69.582.60 ± 29.74
Cycle 1 Day 22—10.55 ± 56.36—
SecondaryTmax of Trametinib

Tmax is defined is the time to maximum plasma concentration

Time frame:
At Cycle 1 Day 1 and Cycle 1 Day 22
Reported as:
Median · hours (h)
Tmax of Trametinib
hours (h)Dose Level 1Dose Level 2Dose Level -2a
Cycle 1 Day 11.50 (1.00 to 2.00)2.00 (1.00 to 2.00)2.00 (2.00 to 2.00)
Cycle 1 Day 22—2.50 (1.00 to 4.00)—
SecondaryAUC 0-24 of Trametinib

Area under the plasma concentration time-curve. AUC from time 0 to 24 hours after dose.

Time frame:
At Cycle 1 Day 1 and Cycle 1 Day 22
Reported as:
Geometric mean · h*ng/mL
AUC 0-24 of Trametinib
h*ng/mLDose Level 1Dose Level 2Dose Level -2a
Cycle 1 Day 188.77 ± 6.4820.58 ± 36.1919.27 ± 13.47
Cycle 1 Day 22—197.45 ± 45.52—

Adverse events

Collected over From first dose to 28 days after last dose, approximately 9.5 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dose Level 12/2 (100%)0/2 (0%)2/2 (100%)
Dose Level 22/5 (40%)1/5 (20%)5/5 (100%)
Dose Level -2a1/2 (50%)2/2 (100%)2/2 (100%)
Most frequent serious events
Most frequent serious events
EventDose Level 1Dose Level 2Dose Level -2a
Abdominal painGastrointestinal disorders0/20/51/2
AstheniaGeneral disorders0/20/51/2
Atrial fibrillationCardiac disorders0/21/50/2
DyspnoeaRespiratory, thoracic and mediastinal disorders0/21/50/2
Most frequent other events
Showing 10 of 51
Most frequent other events
EventDose Level 1Dose Level 2Dose Level -2a
NauseaGastrointestinal disorders2/22/51/2
VomitingGastrointestinal disorders2/22/51/2
AnaemiaBlood and lymphatic system disorders1/22/50/2
VertigoEar and labyrinth disorders0/20/51/2
ConstipationGastrointestinal disorders1/22/50/2
DiarrhoeaGastrointestinal disorders1/21/50/2
Dry mouthGastrointestinal disorders1/20/50/2
AstheniaGeneral disorders0/22/51/2
Catheter site oedemaGeneral disorders0/20/51/2
FatigueGeneral disorders1/22/51/2

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Dose Level 1Dose Level 2Dose Level -2aTotal
Mean59.5 ± 21.9261.8 ± 12.7460.5 ± 13.4461.0 ± 12.84
Sex: Female, Male
Sex: Female, Male(Participants)Dose Level 1Dose Level 2Dose Level -2aTotal
Female2417
Male0112
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Dose Level 1Dose Level 2Dose Level -2aTotal
Hispanic or Latino0000
Not Hispanic or Latino2327
Unknown or Not Reported0202
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Dose Level 1Dose Level 2Dose Level -2aTotal
American Indian or Alaska Native0000
Asian0011
Native Hawaiian or Other Pacific Islander0000
Black or African American1001
White0516
More than one race0000
Unknown or Not Reported1001
08

Study locations

6 sites
  • Local Institution - 2101
    California City, California 90033, United States
  • Local Institution - 2109
    California City, California 92663, United States
  • Local Institution - 2106
    Denver, Colorado 80218, United States
  • Local Institution - 2108
    Nashville, Tennessee 37203, United States
  • Local Institution - 2107
    Houston, Texas 77030, United States
  • Local Institution - 2102
    Virginia Beach, Virginia 22031, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2021 to primary completion in Mar 2023, 17 months.

Results were first posted in Apr 2024, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2021
First posted
Oct 8, 2021
StartActual
Sep 23, 2021
Primary completionActual
Mar 1, 2023
CompletionActual
Mar 1, 2023
Results first posted
Apr 2, 2024
Last update
Apr 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05071183
Responsible party
Sponsor
First posted
Oct 8, 2021
Start date
Sep 23, 2021
Primary completion
Mar 1, 2023
Completion
Mar 1, 2023
Results posted
Apr 2, 2024
Last update
Apr 2, 2024

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Repotrectinib

Start the discussion